Kincell Bio, founded in Gainesville, Florida, is a cutting-edge contract development and manufacturing organization (CDMO) specializing in immune cell therapies. The company’s core mission is to streamline the development and manufacturing processes for therapies including autologous and allogeneic CAR-T, CAR-NK, and CAR-M programs. Kincell Bio offers a comprehensive range of services such as analytical development, process development, CMC consulting, and early-stage GMP cell therapy manufacturing, targeting the biopharmaceutical market.
Notable figures affiliated with Kincell Bio include Mark Bamforth, who serves as the Chairman of the Board of Directors. The company has made significant strides in the biotech industry by combining deep immunotherapy expertise with superior service, making it a preferred partner for early-stage cell therapy programs. Kincell Bio's impact is evident through its contributions to advancing immune cell therapy development and its role in facilitating innovative treatments in the medical field.
